{ "id": "epkyf5wdmg", "slug": "her2-cep17-fish-ratio-assay", "title": "HER2/CEP17 FISH ratio assay", "updated": "2026-10-15", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical" }, { "id": "life.health.clinical.clinical-diagnostics", "label": "Diagnosis and clinical assessment", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-diagnostics" }, { "id": "life.health.clinical.clinical-diagnostics.laboratory-and-in-vitro-diagnostics", "label": "Laboratory and in-vitro diagnostics", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-diagnostics.laboratory-and-in-vitro-diagnostics" } ], "geo": [ { "id": "geo.nongeo.t1946.life.health.clinical.clinical-diagnostics.laboratory-and-in-vitro-diagnostics", "label": "Non-geographic · 1946 to 2000: Laboratory and in-vitro diagnostics", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-diagnostics.laboratory-and-in-vitro-diagnostics", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t1946", "label": "Non-geographic · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946" }, { "id": "geo.nongeo.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life" }, { "id": "geo.nongeo.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health" }, { "id": "geo.nongeo.t1946.life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical" }, { "id": "geo.nongeo.t1946.life.health.clinical.clinical-diagnostics", "label": "Diagnosis and clinical assessment", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-diagnostics" }, { "id": "geo.nongeo.t1946.life.health.clinical.clinical-diagnostics.laboratory-and-in-vitro-diagnostics", "label": "Laboratory and in-vitro diagnostics", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-diagnostics.laboratory-and-in-vitro-diagnostics" } ] } ], "excerpt": "The HER2/CEP17 FISH ratio assay is a dual-probe fluorescence in situ hybridization test measuring HER2 gene signals against chromosome 17 signals to determine breast cancer eligibility for anti-HER2 therapy.", "snippet": "The HER2/CEP17 FISH ratio assay is a dual-probe fluorescence in situ hybridization test measuring HER2 gene signals against chromosome 17 signals to determine breast cancer eligibility for anti-HER2 therapy.", "node": "life.health.clinical.clinical-diagnostics.laboratory-and-in-vitro-diagnostics", "markdown": "# HER2/CEP17 FISH ratio assay\n\nThe HER2/CEP17 FISH ratio assay is a dual-probe fluorescence in situ hybridization test that measures the number of HER2 (ERBB2) gene signals relative to chromosome 17 centromere signals in tumor nuclei, to determine whether a breast cancer is HER2-amplified and therefore eligible for anti-HER2 therapy such as trastuzumab.[1](https://www.ebi.ac.uk/ols4/ontologies/ncit/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FNCIT_C184370?lang=en) • [2](https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100027B.pdf) Both the HER2/CEP17 ratio and the average HER2 copy number per cell are reported and interpreted together: dividing HER2 signals by centromere 17 (CEP17) signals normalizes for the number of chromosome 17 copies in each cell.[3](https://aacrjournals.org/mct/article/5/10/2572/234747/Correction-for-chromosome-17-is-critical-for-the) Under current ASCO/CAP guidance, dual-probe ISH results are assigned to five groups based on both the HER2/CEP17 ratio and the average HER2 copy number, with concomitant IHC review required for groups 2 to 4, and the integrated result drives the decision to treat with HER2-targeted drugs.[4](https://ascopubs.org/doi/10.1200/JCO.2018.77.8738)\n\n| Key fact | Value |\n|---|---|\n| Measured quantity | HER2 (ERBB2) signals divided by chromosome 17 centromere (CEP17) signals in the same tumor nuclei[1](https://www.ebi.ac.uk/ols4/ontologies/ncit/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FNCIT_C184370?lang=en) |\n| Amplified (positive) | Assigned by the five-group algorithm using both the HER2/CEP17 ratio and the average HER2 copy number; groups 2 to 4 require IHC-integrated classification and are not automatically positive[5](https://staging.seer.cancer.gov/eod_public/input/3.2/breast/her2_ish_dp_copy_no/?breadcrumbs=%28%7Eview_schema%7E%2C%7Ebreast%7E%29) |\n| Negative | Ratio <2.0 and average HER2 copy number <4.0 signals/cell[5](https://staging.seer.cancer.gov/eod_public/input/3.2/breast/her2_ish_dp_copy_no/?breadcrumbs=%28%7Eview_schema%7E%2C%7Ebreast%7E%29) |\n| Nuclei counted | At least 20 tumor nuclei; an additional 20 if the ratio falls between 1.8 and 2.2[6](https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190031B.pdf) |\n| Fixation standard | 10% neutral-buffered formalin, 18–24 hours (kit insert); 6–48 hours accepted under the 2007 guideline[7](https://www.leicabiosystems.com/sites/default/files/media_product-download/2021-06/Leica_HER2_FISH_System_TA9217_EU-EN-CE_Rev_H.pdf) • [8](https://gotoper-com.s3.amazonaws.com/_media/_pdf/new_ajho_10.17.17.PDF) |\n| Clinical decision | Eligibility for anti-HER2 therapy (for example, trastuzumab)[2](https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100027B.pdf) |\n| Guideline history | ASCO/CAP guideline first published 2007, updated 2013 and 2018, and further updated in 2023, when the panel reaffirmed the 2018 recommendations[9](https://ascopubs.org/doi/10.1200/JCO.22.02864) |\n\n## How it works\n\nThe assay uses two DNA probes applied to the same tissue section. One probe is locus-specific for the HER2 gene (ERBB2, also called NEU) at 17q12; in the Abbott PathVysion kit it spans the entire gene and is labeled SpectrumOrange, while the second probe hybridizes to alpha satellite DNA at the centromere of chromosome 17 (17p11.1-q11.1) and is labeled SpectrumGreen.[10](https://www.molecular.abbott/us/en/products/oncology/pathvysion-her-2-dna-probe-kit) The VENTANA dual ISH cocktail instead uses HER2 oligo probes spanning approximately 300,000 base pairs, labeled with dinitrophenyl, and chromosome 17 probes labeled with digoxigenin, in a formamide-based buffer.[11](https://diagnostics.roche.com/content/dam/diagnostics/us/en/LandingPages/her2-dual-ish/VENTANA-HER2-Dual-ISH-Method-Sheet.pdf)\n\nThe centromere probe is the internal control: because both signals are counted in the same nuclei, the HER2/CEP17 ratio distinguishes true gene amplification from an increased number of chromosome 17 copies, and it also corrects for nuclear truncation, in which a section cuts through the top of a nucleus and removes signals.[10](https://www.molecular.abbott/us/en/products/oncology/pathvysion-her-2-dna-probe-kit) Published comparisons have argued that this chromosome 17 correction is critical for determining true HER2 amplification status, since a single-probe approach counting absolute HER2 copies (more than 4.0 per nucleus) can misclassify tumors.[3](https://aacrjournals.org/mct/article/5/10/2572/234747/Correction-for-chromosome-17-is-critical-for-the)\n\n## How it is done\n\n1. **Fixation and sectioning.** Specimens are sampled at 3–4 mm thickness, fixed for 18–24 hours in 10% neutral-buffered formalin, and sectioned at 4–6 µm on charged slides.[7](https://www.leicabiosystems.com/sites/default/files/media_product-download/2021-06/Leica_HER2_FISH_System_TA9217_EU-EN-CE_Rev_H.pdf) The 2007 ASCO/CAP guideline standardized preanalytic variables including ischemia time and a formalin fixation duration of 6–48 hours.[8](https://gotoper-com.s3.amazonaws.com/_media/_pdf/new_ajho_10.17.17.PDF)\n2. **Pretreatment, denaturation, and hybridization.** In a representative published protocol on 3-µm sections, pretreatment solution is applied for 30 minutes at 98 °C, tissue is digested with pepsin at 37 °C for 20 minutes, probe is applied, slides are denatured at 75 °C for 5 minutes, and hybridized at 37 °C overnight, followed by washes in 0.4× SSC at 72 °C for 2 minutes and 2× SSC with 0.005% Tween-20 for 30 seconds.[12](https://link.springer.com/article/10.1186/s13000-024-01455-8)\n3. **Counting and ratio calculation.** HER2 and CEP17 signals are enumerated in at least 20 tumor nuclei, and the ratio is the sum of HER2 signals divided by the sum of CEP17 signals; for example, 143 HER2 signals over 48 CEP17 signals gives 2.98, a positive result.[6](https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190031B.pdf) • [7](https://www.leicabiosystems.com/sites/default/files/media_product-download/2021-06/Leica_HER2_FISH_System_TA9217_EU-EN-CE_Rev_H.pdf) Signals appear as single copies, multiple copies, or clusters, and single copies in normal cells serve as the enumeration reference.[6](https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190031B.pdf)\n4. **Borderline recount.** If the ratio falls between 1.8 and 2.2, an additional 20 nuclei are counted, for a total of 40.[6](https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190031B.pdf) • [7](https://www.leicabiosystems.com/sites/default/files/media_product-download/2021-06/Leica_HER2_FISH_System_TA9217_EU-EN-CE_Rev_H.pdf)\n\nThe 2013 criteria classified cases as positive with a ratio of 2.0 or more, or a ratio below 2.0 with an average of 6.0 or more HER2 signals per cell, and as equivocal with a ratio below 2.0 and an average of 4.0 to fewer than 6.0 signals.[13](https://pmc.ncbi.nlm.nih.gov/articles/PMC5600490/) The 2018 update organized dual-probe ISH results into five groups: group 1 (ratio ≥2.0, average copy number ≥4.0) is positive and predicts favorable response to targeted therapy; group 5 (ratio <2.0, <4.0 signals/cell) is negative; group 2 is ratio ≥2.0 with average copy number <4.0; group 3 is ratio <2.0 with copy number ≥6.0; and group 4 is ratio <2.0 with copy number ≥4.0 and <6.0.[4](https://ascopubs.org/doi/10.1200/JCO.2018.77.8738) • [14](https://arupconsult.com/ati/erbb2-her2neu-herceptest-testing) For groups 2 to 4, the guideline requires concomitant HER2 IHC review to reach the most accurate designation: IHC 3+ is treated as positive and 0/1+ as negative, and for IHC 2+ cases additional nuclei are enumerated in the area of highest IHC intensity.[4](https://ascopubs.org/doi/10.1200/JCO.2018.77.8738) • [14](https://arupconsult.com/ati/erbb2-her2neu-herceptest-testing)\n\n## Origin\n\nThe dual-probe format reached routine practice through FDA-cleared kits such as the Vysis PathVysion test, which includes a chromosome 17 probe in a dual-color format, and through the argument that chromosome 17 correction is needed to determine true HER2 amplification status.[3](https://aacrjournals.org/mct/article/5/10/2572/234747/Correction-for-chromosome-17-is-critical-for-the)\n\nStandardization came from the ASCO and College of American Pathologists guideline, first published in 2007 and updated in 2013 and 2018.[9](https://ascopubs.org/doi/10.1200/JCO.22.02864) The 2007 guideline was motivated by evidence that approximately 20% of [HER2 testing](https://www.edgepedia.org/her2-testing) at the time might be inaccurate, and it required laboratories to show 95% concordance with another validated test for positive and negative assay values.[15](https://pubmed.ncbi.nlm.nih.gov/17159189/)\n\n## Variants\n\nSeveral dual-probe platforms are in routine use. PathVysion (Abbott) pairs a SpectrumOrange LSI HER-2 probe with a SpectrumGreen CEP 17 probe, and FDA-approved automated result scanning is available for it; in the Vysis kit, the CEP17 probe is D17Z1.[10](https://www.molecular.abbott/us/en/products/oncology/pathvysion-her-2-dna-probe-kit) • [5](https://staging.seer.cancer.gov/eod_public/input/3.2/breast/her2_ish_dp_copy_no/?breadcrumbs=%28%7Eview_schema%7E%2C%7Ebreast%7E%29) The Leica HER2 FISH System uses an LSI HER2/CEP17 Dual Probe for same-cell analysis.[7](https://www.leicabiosystems.com/sites/default/files/media_product-download/2021-06/Leica_HER2_FISH_System_TA9217_EU-EN-CE_Rev_H.pdf) The CytoCell (Oxford Gene Technology) probe uses a 347 kb red-labeled HER2 probe plus a green chromosome 17 centromere probe.[16](https://www.ogt.com/products/product-search/cytocell-her2-erbb2-amplification-fish-probe/) The VENTANA dual ISH runs on automated slide stainers and was FDA-approved for enumerating the HER2-to-chromosome 17 ratio in FFPE (formalin-fixed, paraffin-embedded tissue specimen) breast tissue when trastuzumab treatment is being considered.[2](https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100027B.pdf) IQFISH, a fast-hybridization format, reduces hybridization time to 1 hour with 98% concordance with conventional FISH.[17](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2013.00129/full)\n\n## Applications\n\nThe assay's primary application is determining eligibility for anti-HER2 therapy such as trastuzumab in breast cancer.[2](https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100027B.pdf) Beyond breast cancer, the same ratio approach is applied to gastric and gastroesophageal-junction adenocarcinomas.[7](https://www.leicabiosystems.com/sites/default/files/media_product-download/2021-06/Leica_HER2_FISH_System_TA9217_EU-EN-CE_Rev_H.pdf)\n\n## Limitations and alternatives\n\n**Polysomy 17 and CEP17 gain.** An increased CEP17 signal count, operationally three or more chromosome 17 centromere signals per cell, does not by itself establish whole-chromosome polysomy, since regional gain around the centromere can produce extra signals.[18](https://pmc.ncbi.nlm.nih.gov/articles/PMC3885470/) By dual-color FISH, a mean CEP17 copy number above three is seen in approximately 8% of breast cancer specimens, mostly among tumors with four to six HER2 gene copies.[17](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2013.00129/full) However, microarray comparative genomic hybridization showed that extra CEP17 signals are more often caused by CEP17 gain or amplification (38.9/55.5%) than by true chromosome 17 polysomy (5.5%), which can mislead the HER2/CEP17 ratio and preclude anti-HER2 therapy for some patients.[17](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2013.00129/full) Conversely, in chromosome 17 monosomy the ratio can exceed 2.0 or 2.2 without underlying HER2 amplification, and HER2-amplified tumors with monosomy 17 respond poorly to trastuzumab-based treatment, so absolute HER2 copy number should be used in those cases.[17](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2013.00129/full) When CEP17 performance is problematic, other chromosome 17 genes such as TP53 and [RARA](https://www.edgepedia.org/rara) can be used to assess borderline ratios.[5](https://staging.seer.cancer.gov/eod_public/input/3.2/breast/her2_ish_dp_copy_no/?breadcrumbs=%28%7Eview_schema%7E%2C%7Ebreast%7E%29) It remains uncertain whether patients in group 4 (ratio <2.0, 4.0–6.0 average signals) benefit from HER2-targeted therapy in the absence of IHC 3+ protein overexpression.[14](https://arupconsult.com/ati/erbb2-her2neu-herceptest-testing)\n\n**Preanalytic and image quality.** Testing is validated only for FFPE specimens fixed in 10% neutral-buffered formalin, and decalcified specimens may yield false-negative results.[14](https://arupconsult.com/ati/erbb2-her2neu-herceptest-testing) Low image quality, blurred or overlapping signals, amplification clusters, and autofluorescence background cause inter-observer variability and inaccurate counts.[12](https://link.springer.com/article/10.1186/s13000-024-01455-8) Concordance between IHC and FISH varies because IHC interpretation is subjective; IHC 2+ triggers reflex FISH testing.[14](https://arupconsult.com/ati/erbb2-her2neu-herceptest-testing)\n\n**Alternatives.** FISH is widely described as the gold standard for HER2 status, but it requires a fluorescence microscope, cytogenetic skills, specific training, and time, and it is expensive.[10](https://www.molecular.abbott/us/en/products/oncology/pathvysion-her-2-dna-probe-kit) • [19](https://link.springer.com/article/10.1186/1471-2407-13-351) In a prospective multicenter study of 840 breast core biopsies across 15 French centers, concordance with FISH was 97–98% for SISH, 98% (ratio) but 75% (copy number) for CISH, and 95–93% for qPCR, and specificity was 97% for all three when FISH was expressed as the HER2/CEN17 ratio.[19](https://link.springer.com/article/10.1186/1471-2407-13-351) FDA-approved brightfield dual in situ hybridization (DISH) for ERBB2 and CEN17 is also available.[20](https://www.sciencedirect.com/science/article/abs/pii/S0933365723000829) NGS-based ERBB2 copy number, compared against IHC and/or FISH positivity in 1,108 breast cancers, showed 95.7% sensitivity, 94.2% specificity, and 94.9% overall agreement; FISH copy numbers plateau beyond about 25 signals per nucleus, limiting resolution at high amplification levels.[21](https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2026.1873228/full) Automated image analysis of HER2 FISH has developed over two decades, and super-resolution image processing can change classification: in one study using the HM-1000 system, three samples were classified as group 2 (formerly called monosomy) on super-resolution images, and two of them had been classified as HER2 non-amplified from conventional-resolution images.[12](https://link.springer.com/article/10.1186/s13000-024-01455-8) Deep-learning approaches are also emerging, and pathology foundation models could predict CEP17 polysomy directly from H&E images.[22](https://www.nature.com/articles/s41523-026-01036-6.pdf) [Resolution](https://www.edgepedia.org/resolution) and background-noise limitations from tissue autofluorescence remain unresolved for automated counting.[12](https://link.springer.com/article/10.1186/s13000-024-01455-8)\n\n## References\n\n1. [NCIt: C184370, HER2/CEP17 dual-probe FISH assay definition](https://www.ebi.ac.uk/ols4/ontologies/ncit/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FNCIT_C184370?lang=en)\n2. [Summary of Safety and Effectiveness Data (SSED) for INFORM HER2 Dual ISH DNA Probe Cocktail (P100027)](https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100027B.pdf)\n3. [Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer](https://aacrjournals.org/mct/article/5/10/2572/234747/Correction-for-chromosome-17-is-critical-for-the)\n4. [HER2 Testing in Breast Cancer: ASCO/CAP Clinical Practice Guideline Focused Update (2018)](https://ascopubs.org/doi/10.1200/JCO.2018.77.8738)\n5. [HER2 ISH Dual Probe Copy Number | SEER*RSA](https://staging.seer.cancer.gov/eod_public/input/3.2/breast/her2_ish_dp_copy_no/?breadcrumbs=%28%7Eview_schema%7E%2C%7Ebreast%7E%29)\n6. [Draft Summary Basis for Approval, VENTANA HER2 Dual ISH (P190031B)](https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190031B.pdf)\n7. [Leica HER2 FISH System - 30 Test (package insert)](https://www.leicabiosystems.com/sites/default/files/media_product-download/2021-06/Leica_HER2_FISH_System_TA9217_EU-EN-CE_Rev_H.pdf)\n8. [Controversies in HER2 Oncogene Testing (The American Journal of Hematology/Oncology)](https://gotoper-com.s3.amazonaws.com/_media/_pdf/new_ajho_10.17.17.PDF)\n9. [HER2 Testing in Breast Cancer: ASCO–CAP Guideline Update](https://ascopubs.org/doi/10.1200/JCO.22.02864)\n10. [PathVysion HER-2 DNA Probe Kit | Abbott Molecular](https://www.molecular.abbott/us/en/products/oncology/pathvysion-her-2-dna-probe-kit)\n11. [VENTANA HER2 Dual ISH DNA Probe Cocktail Method Sheet (Roche)](https://diagnostics.roche.com/content/dam/diagnostics/us/en/LandingPages/her2-dual-ish/VENTANA-HER2-Dual-ISH-Method-Sheet.pdf)\n12. [Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer](https://link.springer.com/article/10.1186/s13000-024-01455-8)\n13. [Assessment of dual-probe Her-2 FISH in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than by the 2007 guidelines](https://pmc.ncbi.nlm.nih.gov/articles/PMC5600490/)\n14. [ERBB2 (HER2) (HercepTest) Testing, ARUP Test Fact Sheet](https://arupconsult.com/ati/erbb2-her2neu-herceptest-testing)\n15. [ASCO/CAP guideline recommendations for HER2 testing in breast cancer (2007)](https://pubmed.ncbi.nlm.nih.gov/17159189/)\n16. [CytoCell HER2 (ERBB2) Amplification FISH Probe (Oxford Gene Technology)](https://www.ogt.com/products/product-search/cytocell-her2-erbb2-amplification-fish-probe/)\n17. [Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2013.00129/full)\n18. [Impact of polysomy 17 on HER2 testing of invasive breast cancer patients](https://pmc.ncbi.nlm.nih.gov/articles/PMC3885470/)\n19. [SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases](https://link.springer.com/article/10.1186/1471-2407-13-351)\n20. [Detection of ERBB2 and CEN17 signals in FISH and dual in situ hybridization for guiding breast cancer HER2 target therapy](https://www.sciencedirect.com/science/article/abs/pii/S0933365723000829)\n21. [Evaluation of HER2 status and characteristics by next-generation sequencing in breast cancer](https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2026.1873228/full)\n22. [Benchmarking of pathology foundation models for assessing HER2 amplification and CEP17 polysomy in breast cancer](https://www.nature.com/articles/s41523-026-01036-6.pdf)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Clinical assessment and procedures › Diagnosis and clinical assessment › Laboratory and in-vitro diagnostics*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/her2-cep17-fish-ratio-assay", "markdown_url": "https://www.edgepedia.org/her2-cep17-fish-ratio-assay.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"HER2/CEP17 FISH ratio assay\", Edgepedia (EdgeChat), https://www.edgepedia.org/her2-cep17-fish-ratio-assay. Edgepedia Community License 1.0.", "credit_md": "\"[HER2/CEP17 FISH ratio assay](https://www.edgepedia.org/her2-cep17-fish-ratio-assay)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/her2-cep17-fish-ratio-assay](https://www.edgepedia.org/her2-cep17-fish-ratio-assay). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"HER2/CEP17 FISH ratio assay\", Edgepedia (EdgeChat), https://www.edgepedia.org/her2-cep17-fish-ratio-assay. Edgepedia Community License 1.0.", "speakable": "The HER2/CEP17 FISH ratio assay is a dual-probe fluorescence in situ hybridization test measuring HER2 gene signals against chromosome 17 signals to determine breast cancer eligibility for anti-HER2 therapy." }